PDCD1 and neoplasm: Thus, targeting of the immune suppression mechanism, which is generally activated as the cancer fightback mechanism (such as the PD1/PD-L1 pathway) may be combined with chemotherapy or adjuvant therapy and other types of immunotherapies, such as adoptive T cells, chimeric antigen receptor (CAR) T cells, or tumor specific BiTEs.